To evaluate evidence in recent authoritative 'Evidence-Based Medicine' (EBM) reports on surgery for severe obesity. METHODS: Focused review of Index Medicus citations and authors' own databases of publications on surgery for obesity, . RESULTS: EBM criteria for assessment of strength of evidence requiring randomized controlled studies (RCTs) in these reports are inappropriate for evaluating invasive treatments such as surgery, which have robust physiological effects, are difficult to reverse and may have more serious side effects than the drug studies for which the criteria were promulgated. Flaws in these reports include omissions of important studies demonstrating improvements in comorbidity, factual errors in descriptions of operations and faulty analyses of outcomes of laparoscopic approaches. There are misinterpretations of cited papers, and inclusion of obsolete operations as well as a study generated during the 'learning curve' of an avowed complex procedure. CONCLUSION: EBM analyses of surgical modalities affecting access to care require relevant evaluation criteria, true peer review and expert consultation. Authors' claims of objectivity by invoking use of evidence-based criteria applicable to drug treatment and other easily reversible forms of therapy are questionable. Decisions based on flawed EBM reports may adversely affect access to care for millions of severely obese patients.
Introduction
We have serious concerns about four recent evidence-based medicine (EBM) reports (Table 1) because we believe their conclusions have led to the restriction of access to care, thus depriving patients of needed services. Two reports were sponsored by Blue Cross, Blue Shield, Kaiser Foundation Health Plan and Southern California Permanente Medical Group through their Technology Evaluation Center (TEC) and were titled: 'The relationship between weight loss and changes in morbidity following bariatric surgery for morbid obesity' 1 and 'Newer techniques in bariatric surgery for morbid obesity'. 2 One, entitled 'Health outcomes after bariatric surgery', was developed by Winfred S Hayes Inc., offering paid subscriptions almost exclusively to United States Health Insurance Companies. 3 The fourth is a Cochrane report by
Clegg et al, 'Clinical and cost effectiveness of surgery for morbid obesity: a systematic review and economic evaluation'. 4, 5 Cochrane reports are highly regarded as unbiased reviews of various treatments designed to provide 'patients, health professionals and the public with guidance on current best practice'. Each of these four EBM reports has significant flaws including omissions of data, factual errors, faulty analyses and inclusion of obsolete operations.
Methods
We used PubMed r to access Index Medicus for the years 1978-2003, using search words under each of the obesity comorbidities listed in Table 2 , as well as the names of various operative procedures used for the treatment of severe obesity (Table 3 ). In addition, we included our personal files of peer-reviewed published studies in these areas of interest. Both retrospective and prospective studies were evaluated, excluding case reports. Randomized controlled trials (RCTs) discussed in the EBM reports were assessed regarding the issues of equipoise and blinding, as well as current accepted procedures and data concerning the techniques under consideration. We identified flaws in cited publications as well as improper use of exclusion criteria.
Results
The four recent EBM studies are summarized in Table 1 . Three were industry sponsored or supported, [1] [2] [3] whereas the Cochrane report was sponsored by the National Institute for Clinical Excellence (NICE) for the National Health Service of the United Kingdom. 4, 5 Table 2 . 17 all found gastric bypass to cause greater weight loss than gastroplasty. One study not cited by either report found an equivalent weight loss between vertical banded gastroplasty and gastric bypass when patients were allowed to choose the operation, but the drop-out rate (15% seen at 5 y) was excessive. 93 The only nonrandomized trial comparing the laparoscopic-adjustable gastric band to gastric bypass concluded that gastric bypass caused significantly greater weight loss.
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Effects of bariatric surgery on obesity comorbidity Each of the reports acknowledges the improvement in obesity comorbidity with surgical weight loss. However, their endorsement of this fact is guarded. Unfortunately, each of these EBM studies omitted a large number of manuscripts documenting both short-and long-term efficacy of bariatric surgery in reducing numerous obesity comorbidities ( Table 2) . Each of the EBM reports praises the Swedish Obese Subjects (SOS) intervention cohort study in which surgically treated patients are matched with nonsurgical patients according to 18 clinical variables, 94 recognizing that SOS is not an RCT.
Each study cites improvement in most comorbidities and quality of life in the surgical arm of the SOS study, whereas they report failure of control of hypertension over the long term. 23 Analysis of this important comorbidity reveals that 94% of the patients in the SOS study underwent vertical banded gastroplasty or gastric banding and only 6% gastric bypass. The latter group has had a significantly greater weight loss throughout the study, and has maintained a significant decrease in both systolic and diastolic blood pressure at 5 y after surgery. 17 A more critical reading allows the conclusion that hypertension indeed is reduced over the long-term by gastric bypass, while the purely restrictive procedures fail to control it beyond 2 y. It is true that the TEC report included this caveat in its Table 6 ; however, it fails to include it in the 'Executive Summary'.
Clegg et al (Cochrane) report. Other than improvement in quality of life years (QALY), Clegg et al 4 only included an econometric analysis of the effect of weight loss surgery on the reduction in cost of medications required for treating type 2 diabetes mellitus (T2DM), while omitting many other comorbidities from their analysis ( Table 2 ). Even so, the authors excluded many studies of T2DM, not including one of several sequential series published by Pories and his colleagues, 45, 48, 6, 49 confirming the efficacy of obesity surgery for this comorbidity. One of those studies demonstrated a mortality difference between operated and unoperated patients, in favor of operation. 6 The Clegg et al report only included the costs of medications for T2DM in the Evidence-based medicine obesity surgery critique HJ Sugerman and JG Kral econometric analysis, as indicated in the title of this paper. In doing so, however, it did not mention the long-term economic benefits of reducing the substantial costs of many of the complications of T2DM (retinopathy, renal disease, neuropathy, coronary artery and peripheral vascular disease). Furthermore, the exclusion from the analysis of numerous other obesity comorbidities, documented to benefit from surgical weight loss such as sleep apnea, thromboembolism and liver disease, underestimates the true value of surgery for severe obesity.
In Table 1 of their report, Clegg et al record regain of all weight by 5 y (to BMI of 45 kg/m 2 ), at variance with all published studies. Possibly this was related to their method for handling missing data in the 14 of 18 series lacking 5 y weight loss in their limited review. However, they excluded several large studies demonstrating percent excess weight loss of approximately 60% at 5 y 39, 45, 95 and 50% at 10 y. 45 Hayes report. The Hayes report states that: 'There is evidence of a significant and sustained benefit of bariatric surgery for patients with disorders of glucose metabolism, such as diabetesyThere is less evidence that bariatric surgery leads to a sustained improvement in other conditions, such as hypertension and adverse lipid profiles'. 3 Later in the executive summary it is stated that: 'ythe following HAYES Ratingst have been assigned: B for bariatric surgery as a means to resolve or alleviate serious obesity-related comorbidities involving abnormal glucose metabolism, such as type 2 diabetes. A D Rating has been assigned to bariatric surgery as a means to resolve or alleviate other comorbidities. This latter rating reflects the lack of evidence regarding long-term efficacy of bariatric surgery for these conditions'. The Hayes report limited its analysis to studies published from 1999 to 2003, 3 thereby eliminating the reports presented at the 1991 National Institutes of Health (NIH) Consensus Conference on the Surgical Treatment of Obesity, 96 as well as numerous other studies (Table 2) . Furthermore, a number of relevant reports during the time period selected were not included in their review.
TEC report. Although the TEC report concluded that surgery improves health in severely obese patients, it arbitrarily excluded numerous relevant studies with fewer than 25 patients or absence of a prospective design (Table 2) . Thus, a study of right heart catheterization in patients with obesity hypoventilation syndrome revealing significant decreases in pulmonary artery, central venous and capillary wedge pressures associated with normalization of arterial blood gases was not included. 27 Similarly, a study of patients with pseudotumor cerebri who underwent measurement of lumbar cerebrospinal fluid opening pressures noting significant decreases associated with relief of headache and pulsatile tinnitus, 73 as well as a study of women with urinary incontinence with significantly decreased urinary bladder pressure postoperatively, 73 was also excluded. The complex nature and risks of physiological studies like these, as well as the difficulties of patient recruitment and financing of the studies after surgical 'cure' of the conditions in question, preclude series of 25 or more patients. The TEC report also concluded: 'it is not possible to draw conclusions as to the relation of increment of weight loss to the increment of improvement in health outcome measures. It is also not possible to identify a weight loss threshold for success of a surgical procedure'. There are, however, data from the SOS study showing that greater weight loss is more likely to control hypertension. 17 Other studies published since these EBM reports have shown better control of T2DM and hypertension with greater weight loss.
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Evaluation of newer techniques in bariatric surgery The risks and benefits of laparoscopic gastric bypass, that is, the early benefits of the laparoscopic vs the open approach, are omitted in the TEC study. This report fails to mention the shorter length of hospital stay, the significant decrease in pain, and wound complications the early improvement in quality of life and earlier return to work with the laparoscopic approach. [79] [80] [81] [82] [83] When evaluating the adjustable laparoscopic gastric band, the authors of the TEC report fail to mention the significantly lower postoperative mortality of 0.05% 97-100 as compared to either the open or laparoscopic gastric bypass (0.5-2%).
Apart from these omissions, there are several errors in the TEC report. The statement concerning the gastric bypass: 'In this procedure, the majority of the stomach is resected (subtotal gastrectomy) and the gastric outlet is attached y' is factually incorrect. The stomach is either transected or stapled ( Figure 1) ; it is not resected (which is a much bigger and potentially more complication-prone surgical procedure). In the figure demonstrating the procedure, it shows an end-to-side jejunojejunostomy (which is correct), but describes incorrectly that it is 'anastomosed end-to-end to the Roux limb'. A typographical error calls an 'anastomotic' leak 'anastigmatic' leak, evidence that no surgeon could have reviewed the text.
When discussing the risks and benefits of the currently performed malabsorptive procedures, the TEC report fails to differentiate between the biliopancreatic bypass developed by Scopinaro and colleagues 101 and the biliopancreatic bypass with duodenal switch (Figure 2 ; Hess and Hess
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). Furthermore, it did not review the data in the large series of these two procedures by Scopinaro et al 101 or Marceau and colleagues. 103 It also made conflicting statements about the three different variants of gastric bypass studied by Brolin et al. 104, 105 Their representation that the 'long-limb' gastric bypass is associated with excessive nutritional and vitamin deficiencies from malabsorption is incorrect, as it refers to the more malabsorptive 'distal' gastric bypass operation 104 Owing to these potential nutritional consequences, it is important to understand the anatomy of these procedures: three 'limbs' or 'tracts' of intestine are created in a Roux-en-Y procedure: the 'Roux' limb, which is attached to the stomach Evidence-based medicine obesity surgery critique HJ Sugerman and JG Kral and is also known as the 'alimentary tract'; the 'biliopancreatic tract' through which the bile and pancreatic juices drain; and the 'common channel' where food is most efficiently absorbed when mixed with the digestive juices ( Figure 1) . In a randomized prospective trial omitted in the TEC report, Brolin and colleagues compared a long-limb gastric bypass with a 35 cm biliopancreatic limb and a 150 cm Roux (alimentary) limb to a standard gastric bypass with a 75 cm Roux limb. 105 This study found that the long-limb gastric bypass caused significantly greater weight loss at years 1, 2 and 3 compared to standard gastric bypass without any evidence of increased nutritional deficiencies.
The group subsequently used a much shorter common channel in a procedure called 'distal' (not long-limb) gastric bypass, causing significantly greater weight loss, but at the expense of nutritional deficiencies from malabsorption. 104 
Discussion
There has been a logarithmic increase in the demand for and performance of surgical procedures for the treatment of obesity. 106 This has been driven by the availability of a more appealing laparoscopic approach, the recognition by referring primary-care physicians that it is the most effective means for treating severely obese individuals, the media exposure of operated obese celebrities and the recognition by general surgeons and hospitals that these procedures are lucrative in a time of decreasing reimbursements. There were approximately 103 000 bariatric surgical procedures in the United States in 2003, a 40% increase from 2002. 106 Spending on bariatric surgery is approaching $3 billion a year, at an average cost of $25 000 for each operation. 107 In contrast, there are approximately 300 000 total knee Figure 1 Gastric bypass with a 10-15 ml pouch created by stapling or transecting stomach, connected to various lengths of intestine. In most procedures, the biliopancreatic limb is 35-75 cm. In the standard gastric bypass, the alimentary limb is 45 cm and in the long-limb gastric bypass it is 150 cm. The junction between the biliopancreatic limb and the alimentary limb forms a 'common channel' where food is most efficiently absorbed when mixed with the digestive juices. In the distal gastric bypass, the biliopancreatic limb is anastomosed to the ileum at various (50-150 cm) distances from the ileocecal valve, creating a shorter 'common channel', which is a more radical malabsorptive procedure. Evidence-based medicine obesity surgery critique HJ Sugerman and JG Kral arthroplasties performed annually 108 at approximately $30 000 for each knee for a cost of $9 billion a year. A recent NIH Consensus Conference concluded that knee arthroplasty is appropriate and effective treatment for individuals with impaired mobility from degenerative disease of the knee. Similar treatment is provided for the hip. We are not aware of any efforts of the health industry to limit access to hip or knee replacements. Severe obesity is a major cause for joint degeneration, so earlier surgery for obesity is preventative in many cases, with the potential for considerable cost reduction. Concomitantly, in addition to preventing a single joint replacement, surgery for obesity resolves or improves large numbers of other, indeed systemic obesity comorbidities ( Table 2 ). The problem is that severe obesity is considered by the public, by physicians and by health insurance carriers alike as a self-induced disease, 109,110 which does not deserve third-party-funded health-care benefits.
The contrast with coverage of smoking-and alcohol-related diseases is telling. The majority of health insurers in the United States appear to have short-planning horizons, possibly because insured individuals and corporate health-care plans frequently change insurance providers. It follows that insurers are unwilling to invest in expensive treatments not yielding profits until after several years. An appropriate concern raised by insurance carriers is the variability in the quality of obesity surgery and the growing number of very expensive, major complications and deaths. 111 As with major pancreatic resectional surgery, 112 it has been shown for obesity surgery that larger volume centers have lower mortality and complication rates than hospitals in which small numbers of procedures are performed. 113, 114 The American Society for Bariatric Surgery has published Guidelines for Granting Privileges in Bariatric Surgery 115 and is developing criteria for Bariatric Centers of Excellence. 116 Supporting highquality surgical programs would be the better direction for health insurance carriers than denying global access to obesity surgery for their impaired customers. Health insurers have sponsored nonpeer-reviewed analyses of the literature or 'evidence' concerning bariatric surgery and have used the conclusions from these reports to deny access for coverage of obesity surgery. 111 Two of these EBM studies were commissioned by Blue Cross/Blue Shield and performed by their own TEC using a panel of 18 advisors, none of whom practice obesity surgery. They then posted the report on the nonpeer-reviewed internet. 1,2 One study was privately funded by Winifred S Hayes Inc., a company whose subscriptions for the service include almost all of the health insurance carriers in the United States. 3 These, as well as the government funded Cochrane reports, 4,5 influence policies and practices for determining third-party reimbursement of health-care expenses related to surgical treatment of obesity.
Flawed analyses such as those described in our analyses, without the benefit of true peer review by bariatric surgeons, unfairly curtail availability of the only effective treatment for the increasing numbers of patients with severe obesity.
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This has the potential to adversely affect the quality of care and provision of services to a very needy population.
RCTs and levels of evidence
EBMs define Level I evidence as evidence that documents efficacy through blinded, RCTs randomizing between two treatment modalities or one treatment and one placebo arm. Whereas outcome assessment can be performed by 'blinded' observers, it would be unethical to disguise the type of operation from the patient. Obviously, surgical procedures can never be blinded and a placebo can never be an ethical option. Both the Cochrane report and the TEC studies lament the lack of RCTs in bariatric surgery. However, the RCT is not an appropriate standard of evidence for evaluating most surgical treatment, which of necessity must rely on observational 117 or cohort studies, or standards of practice that have empirically been proven safe and beneficial. Numerous 'good' surgical practices have evolved into 'standard of care' without being randomized against placebo or ineffective treatment options. 118, 119 Interestingly, the industry has created a 'Catch-22': bariatric surgery is not reimbursed in the absence of sufficient evidence of efficacy from RCTs, yet bariatric surgery is not reimbursed by health insurance if a patient is entered into a trial. Medicare is not authorized to fund 'clinical research' 120 and the NIH have insufficient funding to pay for bariatric operations as part of RCTs. When reviewing RCTs, it is important to document the relevance and current use of the technology in question. Bariatric surgery has advanced considerably from the early days of the jejunoileal bypass in the 1960s, and the horizontal, unbanded gastroplasty in the late 1970s, and into the present era of laparoscopic approaches with gastric banding and diversionary procedures. Including data from 30 to 40 y ago for the current evaluation of obesity surgery, such as the jejunoileal bypass and the unbanded horizontal gastroplasty, would be analogous to combining data over 100 y for automobiles or 25 y for computers and is a serious methodological mistake.
The Swedish government-commissioned EBM Study 'Treating and Preventing Obesity' has just been published, 121 This study proposes a three-level grading of the strength of evidence: Level 1 ¼ 'strong scientific foundation. Presence of at least two studies with high conclusive value'; Level 2 ¼ 'moderate scientific foundation. Presence of one study with high and at least two studies of intermediate value'; and Level 3 ¼ 'limited scientific foundation. Presence of at least two studies of intermediate value'. The Swedish report clearly concludes, based on Level 1 strength of evidence, that surgical treatment causes greater weight loss than nonsurgical methods and almost completely normalizes blood glucose in T2DM. At an intermediate level of strength (Level 2), the report determined that surgical treatment has a large positive effect on health-related quality of life. 121 The
12-member project group that reviewed the evidence
Evidence-based medicine obesity surgery critique HJ Sugerman and JG Kral consisted of six members with expertise in obesity, two of whom had specific experience in the management of bariatric surgery programs. This commission, thus, had expert peer review. In a country known for its socialized medicine and education (only 6% of MD's are involved in private practice; all education and the dominant proportion of research is publicly funded; a negligible minority of health-care providers derive any income from industry consultation), it is unlikely that strong economic forces can influence the opinions of experts. A similar positive government-contracted evaluation of bariatric surgery, with adequate bariatric surgical peer review, was recently submitted to the Agency for Healthcare and Quality (AHRQ) by the RAND Evidence-based Practice Center.
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Omissions and limitations What scientific basis did the Blue Cross, Blue Shield TEC center have for limiting the scope of its review of comorbidity studies to those with Z25 patients or prospective studies (Table 2) ? What 'evidence' drove the Hayes Company to limit their review of improvement in comorbidities to studies published since 1999? How can they justify a grade of D for the effects of bariatric surgery on obesity comorbidity other than T2DM when they failed to review a vast amount of data clearly demonstrating that surgically induced weight loss had profound beneficial effects on almost all of the obesity comorbidities and these effects were long lasting (Table 2) ? How did the Cochrane report justify limiting their analysis of econometric benefits of bariatric surgery to the early improvement in QALY and reduction in costs for medications for T2DM? The improvement in other comorbidities clearly improved the psychological and health-related quality of life gained, much more so than alluded to in the Cochrane, Hayes or TEC reports. Clearly, the omissions in these reports negatively influenced the perception of the value of bariatric surgery, leading some insurance carriers to deny surgery for obesity. 110 In the United Kingdom, a number of Primary-Care Trusts with fixed budgets do not fund obesity surgery despite the conclusion of NICE, based on the Cochrane report, that the surgery was effective. Had the Cochrane report included all of the available studies on the efficacy of obesity surgery for reversing obesity comorbidities in their review, the conclusion would likely have been much stronger, leading to less resistance toward paying for the operations. The omissions have resulted in many United Kingdom citizens being denied needed care. There are several omissions in the TEC discussion of the laparoscopic approaches in bariatric surgery as mentioned earlier. The study did not mention the significantly lower mortality risk with the laparoscopic-adjustable gastric band when compared to either the open or laparoscopic gastric bypass. Thus, placement of an adjustable laparoscopic gastric band may be safer for frail, high-risk patients. When analyzing the risks and benefits of laparoscopic gastric bypass, the early benefits of the laparoscopic vs the open approach [79] [80] [81] [82] [83] were ignored in the TEC study, through not including decreased postoperative pain, decreased wound complications and earlier improvements in quality of life and return to work. The significant benefits of the laparoscopic approach are driving patients to choose laparoscopicoperations. The significant decrease in wound complications include major wound infections, which can be devastating in the severely obese patient following open bariatric surgery. The marked decrease in incisional hernias should be of significant long-term economic benefit to the health insurer as well as clinical benefit to the patient. Another potential major benefit of the laparoscopic approach that is not mentioned in these reports is the observation by laparoscopic surgeons that there are significantly fewer adhesions 123 after laparoscopic approaches (whether it be for cholecystectomy or bariatric surgery), which will ultimately lead to a lower frequency of small bowel obstruction and risk of intestinal infarction or the occasional development of a 'frozen abdomen', the nemesis of gastrointestinal surgeons. The TEC report was superficial and incomplete in its review of malabsorptive procedures, omitting relevant articles [101] [102] [103] and failing to describe accurately the 'longlimb gastric bypass'. 104, 105 The TEC report implies that a number of complications are specific to these malabsorptive procedures ('gastric obstruction, leaks at the anastomotic sites and nausea/vomiting caused by the altered stomach physiology', etc), but these complications are seen with equal frequency with all of the other bariatric bypass procedures. The TEC report on 'Newer techniques in bariatric surgery for morbid obesity' 2 concluded that 'laparoscopic gastric bypass or laparoscopic gastric banding' did not meet their criteria to 'improve outcomes as compared to open gastric bypass', and that the 'bilio-pancreatic diversion, or longlimb gastric bypass' did not meet their criteria' to 'improve outcomes for patients with super-obesity'. These statements have led to decisions by Blue Cross, Blue Shield of California and Blue Cross, Blue Shield Federal Tricare that laparoscopic gastric bypass, laparoscopic adjustable gastric banding, biliopancreatic diversion and long-limb gastric bypass were 'experimental' and, therefore, not eligible for insurance coverage (HJS personally reviewed denial letters for patient coverage to surgeons). Blue Cross, Blue Shield of Florida has recently decided that no surgery for severe obesity should be covered because it has not been shown to be effective and the complication rates are excessive. 110 The result of these flawed reviews is that patients with severe obesity are being denied needed coverage for their disabling conditions. What is the long-term benefit of obesity surgery? In a study from the Netherlands, data after vertical banded gastroplasty predicted an increased quality of life and an increase of 3.6 life-years, so that the surgical treatment of morbid obesity should save approximately $4000 per QALY and result in a $2765 average productivity gain as a result of Evidence-based medicine obesity surgery critique HJ Sugerman and JG Kral an increase in the percentage of patients performing paid labor. 124 The SOS noted a significant decrease in sick leave and disability pension in patients following the surgical treatment of obesity, particularly in subjects aged 47-60 y.
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There were significant reductions in medication for T2DM and cardiovascular disease, but increases in other medication resulted in similar total costs for surgically and conventionally treated patients in the SOS trial due to higher costs for gastrointestinal tract disorder, anemia and prevention of vitamin deficiencies. 125, 126 Average weight reduction of 16.7% in the surgically treated patients did not reduce hospitalization costs in the SOS trial over 6 y. 125 After exclusion for the surgical interventions and conditions common after bariatric surgery, there were no significant differences between the groups in the number of hospital days or hospitalization costs. 127 However, it must be noted that the weight loss of 16.7% in a population of patients having purely restrictive operations is considerably less than the median losses achieved by bypass operations. Since these EBM reports, there have been two additional cohort studies in which patients who underwent obesity surgery were compared to a group of age-, sex-, comorbiditymatched patients who were morbidly obese but did not undergo surgery, one from the State of Washington 7 and one from Canada. 8 In contrast to the SOS study, which was almost entirely purely gastric restriction, 127 both the Washington State and Canadian studies were predominantly gastric bypass, which is associated with greater weight loss. [86] [87] [88] [89] [90] [91] [92] In the Canadian study, there was a 45% decrease in total health-care expenditures in the surgically treated cohort. 8 Both studies noted a significantly lower mortality in the surgical patients. Furthermore, the Canadian study showed for the first time a clinically significant decrease in the risk of developing cancer and infectious diseases, as well as the previously demonstrated decrease in the development of endocrine or cardiovascular diseases in the surgically treated cohort. 8 In addition to these studies, there has also been a meta-analysis documenting the improvement in T2DM, hyperlipidemia, hypertension and sleep apnea. 25 Nevertheless, data available at the time of the studies we criticized above provided ample evidence of the safety and efficacy of bariatric surgery.
Conclusion
We have concerns regarding the validity of health insurance industry-sponsored 'EBM' reviews of surgical procedures lacking adequate surgical peer review. We are also concerned about the validity of government-sponsored EBM studies without true peer review. Furthermore, journals have a responsibility to insure adequate peer review before accepting manuscripts for publication, regardless of topic. We suggest that Level 1 evidence or Grade A recommendations concerning interventions that significantly alter anatomy and/or physiology in a lasting manner be based on a 'preponderance of evidence' or 'dramatic treatment effects', evaluated through peer review by nonconflicted reviewers, including experts with experience of the interventions in question. And, if the EBM review is in conflict with any of the peer reviewer(s), journals should be required to provide concomitant publication of dissenting opinion(s). From our personal hands-on experience with surgical treatment of obesity, we are convinced that such equitable criteria will improve the quality of decisions governing the availability of effective treatment for millions of needy patients. In summary, each of these 'EBM' evaluations of the effectiveness of surgical procedures for the treatment of morbid obesity was, in fact, superficial without true peer review or consultation with experts in the field. Numerous relevant studies were excluded and errors were pervasive. Misstatements regarding the operative procedures and serious omissions of data were also made. EBM analyses require a high quality of peer review and consultation and should not be accepted as true just because the authors state that they are 'evidence based' and purport these to be unbiased, balanced, accurate and thorough. The consequences of poor review are devastating for large numbers of severely obese patients.
